FDMT 4D Molecular Therapeutics Inc

$FDMT $CLDX So I sell out of FDMT to get into CLDX, thinking I'll go back to FDMT after the readout, and the next day CLDX goes down after a good readout (???) and FDMT jumps a level. Fun times.

$FDMT— Headline summary from the September 9 management call and additional highlights: 🔹 PHASE 3 WET-AMD PROGRAM FULLY ENROLLED Both pivotal trials are fully enrolled. 4FRONT-1 is expected to read out in Q2 2027, followed by 4FRONT-2 in 2H 2027. 🔹 PHASE 3 ENRICHED FOR THE STRONGEST-RESPONDING POPULATION 4FRONT-1 consists entirely of treatment-naive patients. In Phase 2, recently diagnosed patients achieved treatment-burden reductions in the mid-80% range through two years while preserving vision. 4FRONT-2 includes both treatment-naive and previously treated patients to support European regulatory requirements. 🔹 CONVENTIONAL, ACHIEVABLE PRIMARY ENDPOINT The primary endpoint is BCVA non-inferiority versus on-label q8-week Eylea at week 52. The major commercial differentiator will be the reduction in supplemental Eylea injections while maintaining vision and anatomical control. 🔹 POTENTIAL 70–90% REDUCTION IN INJECTIONS Management believes a 70–90% reduction in treatment burden would be clinically meaningful regardless of whether patients currently receive injections every 4, 6, 8, 12 or 16 weeks. This could represent a genuine modality change—not another incremental dosing extension. 🔹 REAL-WORLD TREATMENT BURDEN REMAINS HIGH Management’s analysis suggests approximately half of Eylea patients receive injections more frequently than every eight weeks. Newer agents may reduce average annual injections by only approximately one. Management also stated that approximately 40% of patients discontinue treatment by 18 months, contributing to preventable real-world vision loss. 🔹 APPROXIMATELY $10B GLOBAL FRANCHISE OPPORTUNITY Eylea/Eylea HD generated approximately $9.55B in worldwide 2024 sales. 4D-150 provides continuous intraocular expression of aflibercept—the validated protein behind Eylea—plus anti-VEGF-C activity from a single intravitreal injection. 🔹 DME PHASE 3 EXPECTED TO COMMENCE BY MONTH-END The DME Phase 3 program adds another major retinal indication using the same product, administration route, manufacturing infrastructure and retina-specialist commercial channel. Positive wet-AMD Phase 3 results could substantially de-risk the DME opportunity. 🔹 FDMT BELIEVES IT CAN COMMERCIALIZE INDEPENDENTLY Management does not believe FDMT requires a strategic partner in either the United States or Europe. Approximately 2,500–3,000 U.S. retina specialists serve the market, allowing coverage with an estimated 100–150-person commercial organization. 🔹 FAVORABLE BUY-AND-BILL INTEGRATION Management expects 4D-150 to fit within the existing Medicare Part B retina workflow, with familiar distribution, storage and intravitreal administration. Although recurring injections generate income for retina practices, a higher-value treatment reimbursed upfront could preserve physician economics while freeing clinic capacity. 🔹 SUBSTANTIAL PRICING FLEXIBILITY Management believes 4D-150 could capture multiple years of therapeutic value, although it does not currently envision a million-dollar—or even $100,000—price. Long-term vision preservation, fewer procedures and improved persistence strengthen the payer value proposition. 🔹 CASH COVERS BOTH PIVOTAL READOUTS FDMT reported approximately $458M in cash with runway into 2H 2028, carrying the company beyond both scheduled Phase 3 wet-AMD readouts. 🔹 ADDITIONAL CATALYSTS • DME Phase 3 initiation by the end of September • Commercial Investor Day on October 21 • 4D-710 cystic-fibrosis update by year-end • 4FRONT-1 Phase 3 results in Q2 2027 • 4FRONT-2 Phase 3 results in 2H 2027 🔹 REVISED SCREEN-GRADE rNPV • Conservative case: approximately $26/share • Base case: approximately $77/share • High-adoption case: approximately $127/share The base case assumes $5.5B in peak wet-AMD sales and $2.5B in peak DME sales—$8B combined versus the existing approximately $10B worldwide Eylea franchise. It does not require complete market replacement. BOTTOM LINE: The Phase 3 program deliberately emphasizes the patients who produced the strongest Phase 2 results. If 4D-150 preserves vision, reproduces major injection-burden reductions and maintains a clean safety profile, it could replace a meaningful portion of the Eylea franchise and become strategically important to every major retina company. At approximately $14, the market appears to assign minimal value to the wet-AMD opportunity after accounting for DME, cash, remaining development costs and platform optionality. Disclosure: For informational purposes only—not financial advice or a recommendation. I may own $FDMT shares. Biotech investing involves significant clinical, regulatory and financial risks. rNPV figures are estimates based on assumptions. Please conduct your own due diligence.